Market Overview

Novavax Announces Management Promotions


Novavax (NASDAQ: NVAX) announced a number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015.

Gregory M. Glenn, M.D. has been named Senior Vice President, Research and Development. Dr. Glenn joined Novavax in July 2010 as Senior Vice President, Chief Scientific Officer and in January 2011, was named Senior Vice President, Chief Medical Officer. Dr. Glenn has 22 years in translational vaccine development, including discovery, preclinical and clinical development in viral, bacterial and parasitic vaccines and has authored over 65 peer-reviewed publications. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired by Intercell in 2008. He began his vaccine research career at the Walter Reed Army Institute of Research, was board-certified in pediatrics and received his medical degree from Oral Roberts University School of Medicine.

Louis F. Fries III, M.D. has been named Vice President, Chief Medical Officer. Dr. Fries was Vice President of Clinical and Medical Affairs when he joined Novavax in April of 2011. He had formerly served as Director of Clinical Development for GSK biologicals following the acquisition of ID Biomedical by GSK in 2005, and previously had been Vice President of Clinical and Regulatory Affairs at ID Biomedical. Dr. Fries received his medical degree from Duke University, has nearly 25 years of experience in the clinical testing and development of human vaccines, and has authored over 60 peer-reviewed publications.

The Company also announced the appointment of D. Nigel Thomas, Ph.D. to Vice President, Clinical Operations. Dr. Thomas also joined the company in April of 2011 as Executive Director, Clinical Operations. Most recently, Dr. Thomas had been Clinical Operations Director at Iomai beginning in 2006 and through its acquisition by Intercell. He has previously held a variety of clinical operation positions in the Biotechnology and CRO industry. Dr. Thomas received his Ph.D. in Biochemistry & Physiology from the University of Reading in the United Kingdom and has overseen numerous vaccine, drug and medical device clinical trials including global Phase 2 and Phase 3 clinical trials for vaccines.

Posted-In: News Management Movers


Related Articles (NVAX)

View Comments and Join the Discussion!

Detroit Auto Show Unveilings Underscore Auto-Makers' Retooling Efforts

Oragenics Declines Comment on Unusual Market Activity